Harel Gadot - 18 Feb 2026 Form 4 Insider Report for Microbot Medical Inc. (MBOT)

Reporting relationship: Chairman, President and CEO, Director
Issuer ticker: MBOT
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:45:22 UTC
Prior SEC filing: 07 Feb 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Harel Gadot

Key filing fact

Harel Gadot filed Form 4 for Microbot Medical Inc. (MBOT) on 20 Feb 2026.

Key facts

This page summarizes Harel Gadot's Form 4 filing for Microbot Medical Inc. (MBOT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 16:45.

Change

Previous filing in this sequence was filed on 07 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690103 Primary reporting owner

Gadot Harel

Relationship: Chairman, President and CEO, Director
Address: C/O MICROBOT MEDICAL INC., 175 DERBY ST., BLD. 27, HINGHAM
Signature: /s/ Harel Gadot
Signature date: 20 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +480,000
Change %
Price: $0.000000
Shares after: 480,000
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 480,000
Exercise price: $2.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.